益赛普治疗前后强直性脊柱炎患者骨代谢指标变化分析

Effect of etanercept on bone metabolism indexes in patients with ankylosing spondylitis

目的:比较早、中期强直性脊柱炎患者经益赛普治疗6个月前后骨代谢指标的变化,探讨益赛普对早、中期强直性脊柱炎患者骨代谢的影响。方法:对医院收治的60例早、中期强直性脊柱炎患者采用益赛普治疗6个月,治疗前后分别检测患者的骨代谢指标:1型前胶原氨基端延长肽(P1NP)、骨钙素(BGP),骨特异性碱性磷酸酶(BALP),β胶原降解产物(β-CTX),并对两次结果进行比较。结果:强直性脊柱炎患者经益赛普治疗后BALP、BGP及P1NP水平升高,β-CTX水平下降,差异有统计学意义(P<0.05)。结论:强直性脊柱炎患者经益赛普治疗后可通过抑制破骨细胞活性,增加成骨细胞的活性,改变了骨吸收为主的高转换状态,可以预防强直性脊柱炎患者骨质疏松的发生。

Objective:To compare the changes of bone metabolism indexes in patients with early to middle stage ankylosing spondylitis before and after 3 months of treatment with etanercept,and to explore the effect of Etanercept on bone metabolism in patients with early to middle stage ankylosing spondylitis.Methods:60 cases of patients with early and middle stage ankylosing spondylitis were treated with etanercept for 3 month,respectively detect and bone metabolism indexes:P1NP、BGP,BALP、β-CTX in these patients were measured before and after treatment with results compared.Results:the levels of BALP,BGP and P1NP were increased and the levels ofβ-CTX were decreased in ankylosing spondylitis patients after treatment with Etanercept,and the differences were statistically significant(P<0.05).Conclusion:Osteoclast activity can be inhibited in ankylosing spondylitis patients after treatment with Etanercept,increases osteoblast activity,the high transition state dominated by bone resorption was changed,thus can prevent the occurrence of osteoporosis in ankylosing spondylitis patients.